glargine clinical trial
Jump to navigation
Jump to search
Introduction
1
European study, 371 patients, mean HgbA1c 8.8%
glargine + oral hypoglycemic agents* vs insulin 70/30 BID alone
mean decrease in HgbA1c at 24 weeks 1.6% vs 1.3% in favor of glargine group
hypoglycemia less frequent in glargine group not blinded, results favored sponsors of study
* metformin + glimepiride
2.
US study, 233 patients, mean HgbA1c 9.7%
glargine QHS vs insulin 70/30 BID
mean decrease in HgbA1c at 24 weeks 2.8% vs 2.4% in favor of insulin 70/30 group
all patients continued oral hypoglycemic agent(s)* not blinded, results favored sponsor of study
* metformin (all patients) + pioglitazone (1/3 of patients)
More general terms
References
- ↑ Journal Watch 25(7):53-54, 2005
Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice- daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005 Feb;28(2):254-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15677775
Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A; INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005 Feb;28(2):260-5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15677776
Davidson MB. Starting insulin therapy in type 2 diabetic patients: does it really matter how? Diabetes Care. 2005 Feb;28(2):494-5. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15677824